This book aims to provide readers with a current overview of
enrolling trials with immune-checkpoint inhibitors in the
preoperative setting of localized bladder cancer, renal cell
carcinoma, and prostate cancer. The advent of immunotherapy has
revolutionized treatments of genitourinary malignancy and evolved
strategies for multidisciplinary management. This book explains
neoadjuvant checkpoint inhibitors in localized genitourinary
cancers, providing insights into the mechanisms of response and
development of resistance of cancer cells to immunotherapy. It
debates optimal trial design of preoperative checkpoint inhibitors
in GU tumors, including optimal endpoints and the role of
pathologic response as a surrogate endpoint of survival. It also
illuminates clinical management of patients with organ-confined GU
tumors, such as side effect management and perioperative safety,
before providing an overview of biomarker use for patient selection
across the early-stage GU malignancies. Lastly, the book provides
the reader with the most up-to-date data emerging from clinical
trials involving immunotherapy in early-stage GU malignancies.
Neoadjuvant Immunotherapy Treatment of Localized Genitourinary
Cancers: Multidisciplinary Management provides a comprehensive
review of the field, serving as a valuable resource for urologists,
medical oncologists, pathologists, fellows in urologic oncology,
upper-level residents training in urology and medical oncology, as
well as pharmacists interested in RCC clinicians.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!